Hence, treatment of KPC mice (a genetically engineered PDAC mouse model) with a CXCR4 inhibitor promoted T cell recruitment into the tumor, enhancing the efficacy of anti-PD-L1 agents, and drastically reducing PDAC progression [276]. The gene discussed is CD274; the disease is neoplasm.